Emergent BioSolutions Gets Anthrax Vaccine Contract Modification Up to $22.3M

What happened

Emergent BioSolutions received a contract modification worth up to $22.3 million to supply BioThrax anthrax vaccine to the Defense Department. The modification exercises an option period under an existing Pentagon contract, with an initial delivery worth around $7.4 million scheduled this year and remaining deliveries expected next year.

Confirmed

Global impact / market context

The contract extends demand for BioThrax and gives Emergent a planned stream of vaccine deliveries across this year and next. Revenue depends on completing those deliveries, while the initial order provides only part of the stated maximum contract value.

Analyst inference

The agreement is a government procurement contract, meaning a public agency buys supplies from a company. Its staged deliveries tie potential sales to delivery timing; the article gives no profit, production-cost, or broader financial guidance, so the effect on earnings is unclear.

Analyst inference

What to watch

1. Whether Emergent completes the initial BioThrax delivery this year, which would turn the scheduled order into supplied product and support the contract's near-term revenue. Analyst inference
2. Whether the remaining deliveries take place next year as expected, since delays could shift sales timing and alter the pace of cash received. Analyst inference
3. Any further contract details on delivery amounts or timing, which could clarify how much of the up-to-$22.3 million value is realized in each period. Analyst inference

Evidence

• Original source link unavailable